CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript:
以下是caredx, Inc (CDNA) Q3 2024 業績會交易簡報:
Financial Performance:
金融業績:
CareDx reported Q3 revenue of $82.9 million, a 23% year-over-year growth.
Adjusted EBITDA was $6.9 million, substantially above the EBITDA-neutral guide.
Generated $12.5 million in cash from operations and ended with $241 million in cash and cash equivalents.
caredx報告Q3的營業收入爲8290萬美元,同比增長23%。
調整後的EBITDA爲690萬美元,遠高於EBITDA中立的指引。
從運營中獲得了1250萬美元的現金,最終現金及現金等價物達24100萬美元。
Business Progress:
業務進展:
Delivered approximately 44,600 tests, up 16% from the previous year.
Added 15 of a planned 30 sales and marketing team members to promote transplant solutions.
Collaboration with the University of California Health System to implement MedActionPlan.
提供了約44,600項測試,比去年增長了16%。
增加了30名計劃內的銷售和市場團隊成員中的15名,以推廣移植解決方案。
與加州大學醫療系統合作,實施MedActionPlan。
Opportunities:
機會:
Coverage from Medicare and Medicaid Services reaffirmed for solid organ transplant monitoring.
Expanded commercial covered lives by four million in Q3. Highmark Blue Cross Blue Shield recently expanded coverage for AlloSure Kidney and HeartCare.
Medicare和Medicaid Services的覆蓋範圍已確認用於固體器官移植監測。
第三季度將商業覆蓋人數擴大了四百萬。Highmark藍十字藍盾最近擴大了AlloSure腎臟和HeartCare心臟的覆蓋範圍。
Risks:
風險:
No explicit risks detected.
沒有發現任何明確風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。